R. & D. Biocogency Laboratories Inc. Ltd. agreed to acquire an unknown majority stake in Rafarma Pharmaceuticals, Inc. (OTCPK:RAFA) on August 4, 2020. The majority control will be acquired by Biocogency upon completion of Biocogency’s transition to GAAP reporting standards and finalization of acquisition agreements. Rafarma Pharmaceuticals Approves Issuance of Majority of Preferred B shares, conferring voting Shares to Board Chairman Ilya Shpurov, toward the combination of its acquisition by R. & D. BIOCOGENCY LABORATORIES Group.